Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004260.pdf
0001415889-23-004260.rtf
0001415889-23-004260.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004264.pdf
0001415889-23-004264.rtf
0001415889-23-004264.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004262.pdf
0001415889-23-004262.rtf
0001415889-23-004262.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004267.pdf
0001415889-23-004267.rtf
0001415889-23-004267.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004265.pdf
0001415889-23-004265.rtf
0001415889-23-004265.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004266.pdf
0001415889-23-004266.rtf
0001415889-23-004266.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-025682.pdf
0001104659-23-025682.rtf
0001104659-23-025682.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-024756.pdf
0001104659-23-024756.rtf
0001104659-23-024756.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-3ASR

S-3ASR

 View HTML
0001104659-23-023051.pdf
0001104659-23-023051.rtf
0001104659-23-023051.xls
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001104659-23-023064.pdf
0001104659-23-023064.rtf
0001104659-23-023064.xls